Latest news and articles about Salubris Pharmaceuticals
Total: 1 articles found
Shenzhen Salubris Pharmaceuticals shares hit consecutive limit-down floors after its flagship heart failure drug failed to show statistically significant results in Phase II trials. The sell-off reflects growing investor impatience with China's biotech sector as companies struggle to transition from generics to true innovation.
